Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Capecitabine Maintenance in mCRC
NCT06115733Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Shanghai General Hospital. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06115733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115733.